The failed P2TD trial for Travelan and the strategic pivot to a three-times-daily regimen create uncertainty around the BLA pathway. The IMM-529 IND approval and ProIBS distribution deal provide pipeline optionality, but the company remains pre-revenue on prescription products. Monitor the End-of-Phase 2 FDA meeting outcome and any partnership announcements for IMM-124E or IMM-529.
Price Chart
Executive Summary
Immuron Ltd filed its annual report on Form 20-F for the fiscal year ended June 30, 2026. Revenue increased 6% to A$7.7M, net loss improved 29% to A$3.7M, and cash position strengthened to A$9.0M from A$2.8M. The company highlighted record Travelan sales, FDA IND approval for IMM-529, and a strategic reset toward profitability, but remains pre-profit with accumulated losses of A$85.0M and the P2TD field trial for Travelan failed to meet its primary endpoint.
Key Facts
- Revenue from contracts with customers increased 6% to A$7,713,601 for FY26 (FY25: A$7,287,002).
- Net loss improved 29% to A$3,679,999 for FY26 (FY25: A$5,215,987).
- Cash and cash equivalents as of June 30, 2026 were A$9,017,814, up from A$2,830,526 as of June 30, 2025.
- Accumulated losses as of June 30, 2026 were A$84,970,154.
- Research and development expenses decreased 46% to A$1,933,440 (FY25: A$3,597,296) reflecting decreased activity after the P2TD study primary endpoint did not reach statistical significance in December 2025.
- The P2TD field trial for Travelan (IMM-124E) failed to meet its primary endpoint; the company will not pursue a twice-daily dosing proposal.
- FDA IND approval for IMM-529 (C. difficile) was received in November 2025; a Phase 2 trial is planned.
- A material weakness in internal control over financial reporting was identified relating to inventory accounting.
- The company executed an exclusive U.S. distribution agreement for ProIBS with Calmino Group AB on September 4, 2026.
- The Australian government proposed changes to the R&D Tax Incentive program that may render Immuron ineligible for future refunds.
- Total KMP compensation for FY26 was A$2,007,508 (FY25: A$2,031,640).
- The company raised A$6,475,160 in net cash from financing activities during FY26, primarily through an At-the-Market (ATM) facility.
Financial Impact
Revenue up 6% to A$7.7M, net loss improved 29% to A$3.7M, cash increased to A$9.0M. Accumulated losses A$85.0M.
Risk Factors
- Failed P2TD trial for Travelan creates uncertainty for the BLA pathway and FDA approval timeline.
- Proposed changes to Australian R&D Tax Incentive program may eliminate a key source of non-dilutive funding.
- Material weakness in internal controls over inventory accounting could lead to financial reporting issues.
- Company remains pre-profit with accumulated losses of A$85.0M and may require additional capital.
- Dependence on single manufacturers for key product candidates (IMM-124E, IMM-529).
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001213900-26-102838 |
| Document: ea030539801ex11-1.htm | 0001213900-26-102838 |
| Document: ea030539801ex4-11.htm | 0001213900-26-102838 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.9300 | awaiting T+60 | — | $0.9300 (+0.00%) |
Oct 23, 2026 4d ago | 6-K | $0.9200 | awaiting T+60 | — | $0.9300 (+1.09%) |
Oct 23, 2026 4d ago | 424B5 | $0.9200 | awaiting T+60 | — | $0.9300 (+1.09%) |
Oct 21, 2026 6d ago | 6-K | $0.9490 | awaiting T+60 | — | $0.9300 (−2.00%) |
Oct 16, 2026 11d ago | 6-K | $0.9821 | awaiting T+60 | — | $0.9300 (−5.30%) |
Oct 13, 2026 14d ago | 6-K | $1.04 | awaiting T+60 | — | $0.9300 (−10.58%) |
Sep 24, 2026 4w ago | 20-F | $1.19 | awaiting T+60 | — | $0.9300 (−21.85%) |
Sep 24, 2026 4w ago | 6-K | $1.19 | awaiting T+60 | — | $0.9300 (−21.85%) |
Sep 21, 2026 5w ago | 6-K | $1.26 | awaiting T+60 | — | $0.9300 (−25.90%) |
Sep 4, 2026 7w ago | Press Release | $1.80 | awaiting T+60 | — | $0.9300 (−48.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers